Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
about
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repairPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe evolution of anticoagulant therapyApixaban and oral implicationsThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsExtended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literaturePharmacological prevention of venous thromboembolism in orthopaedic surgeryRivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitorEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationRetrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.The proof for new oral anticoagulants: clinical trial evidence.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study.IT-CARES: an interactive tool for case-crossover analyses of electronic medical records for patient safety.Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty.Update in new medications for primary care.Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyEdoxaban: an update on the new oral direct factor Xa inhibitor.Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial dataIncidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.Thromboprophylaxis and orthopaedic surgery: options and current guidelinesOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Pathways for venous thromboembolic prophylaxis in medical and surgical patients.A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare settingUpdate in perioperative medicine.Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorA randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxabanAn open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
P2860
Q24185998-EDACB8E6-3031-416A-804F-9E14B521C50DQ24632872-37611453-1043-42B0-8052-CAF18F65D303Q26771859-0AD5FC60-EC89-4F0B-879D-E78461E0DBD0Q26780328-444302D2-978D-4A52-A9F2-721D0FF1152BQ26828439-A70D7949-72C7-4E03-AA79-6040F62C9259Q26828817-48FF510F-EA1A-4565-837C-D58D24BB8BEAQ26864411-91BB482B-7390-452E-AD5F-4B9D3E746418Q26995635-D9ED1AAC-AB27-401D-BCC4-36D797E13848Q27003914-9DFEB030-D99A-4268-B720-589EE6B48F73Q27497485-6DE6D734-85E2-4726-B950-C37148D7A7C1Q28083067-707530F3-6F86-4730-BBFD-9DC3B1F9BD5BQ28250157-B0B3B886-C741-4F95-A821-529B7ED08150Q28477868-E4FE3931-0E73-4CA9-B757-B66618EE534FQ30975631-96596CFC-B5AD-4711-A650-89819825D962Q33381801-5517EA54-B2ED-4088-93BD-D4A368A842C7Q33397016-D894AB18-66FD-4BB2-8303-0D6FFD09E713Q33397359-3045F4A6-9285-4EB5-9524-643E40D3D031Q33399029-37DCC838-1631-4683-AE3E-77013A6E3198Q33564876-E3B0E779-68F7-476A-8BFC-FC5C14A22867Q33714792-C610BF95-5853-4F2D-97A1-05219C6083A0Q33730845-F8C09AFB-7BF4-4A7B-BC15-3CF14E9522CCQ33823899-1FEC94D6-F750-49C4-8C02-D464482072E2Q33854667-881825FF-96C4-42CA-AE58-CCC9AC72C176Q33891915-523D7820-E35F-4D4F-8A05-D1C2390908EDQ33935409-1C18075F-3597-494F-A269-8634569D062FQ33984758-39F852C9-66BD-45B6-92DC-A5BFE27C0A96Q34035190-04D753D5-29B4-42BF-94AF-78261726617EQ34088870-0A1EA96E-35C9-4CD9-ACC8-15CC531BF1E5Q34175551-A61F4102-AF97-42E2-AEA8-CB731556A752Q34178148-DCD32DF3-617A-4955-9DC4-78F52D81758BQ34252907-720AB675-5807-4CDD-93B5-FD4EF586B8EDQ34264223-8B0E1FD9-0B8A-47D4-9F56-B874299434EBQ34331430-FF09894F-C5CD-4907-A5FF-1F2047D9643DQ34332729-A1A5551F-3BC4-4A12-B905-C38BC144C02AQ34381344-D49B6019-E083-46B9-B29F-99E3C92A799FQ34531991-90191AC7-8FA9-4DDD-A758-07040D67153CQ34559413-AB0D60AD-AF83-460F-8FFA-3F0EC5B34ADFQ34627624-97A2B99A-93D1-42E9-B3A0-4AB9EBD92E15Q34627780-EEA7B8DD-E94D-4636-9011-3A46640D3B3DQ34629479-21F7FC17-21F8-412B-908E-7DEC426971C3
P2860
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Extended duration rivaroxaban ...... , randomised controlled trial.
@ast
Extended duration rivaroxaban ...... , randomised controlled trial.
@en
Extended duration rivaroxaban ...... , randomised controlled trial.
@nl
type
label
Extended duration rivaroxaban ...... , randomised controlled trial.
@ast
Extended duration rivaroxaban ...... , randomised controlled trial.
@en
Extended duration rivaroxaban ...... , randomised controlled trial.
@nl
prefLabel
Extended duration rivaroxaban ...... , randomised controlled trial.
@ast
Extended duration rivaroxaban ...... , randomised controlled trial.
@en
Extended duration rivaroxaban ...... , randomised controlled trial.
@nl
P2093
P1433
P1476
Extended duration rivaroxaban ...... , randomised controlled trial.
@en
P2093
Ajay K Kakkar
Akos F Pap
Andrea G Soglian
Bengt I Eriksson
Frank Misselwitz
Ola E Dahl
Patrick Mouret
RECORD2 Investigators
Sylvia Haas
P356
10.1016/S0140-6736(08)60880-6
P407
P577
2008-06-24T00:00:00Z